Blue­bird’s star gene ther­a­py pa­tient still do­ing well af­ter 15 months-plus; Take­da, Ar­ix part­ner on biotech star­tups

→ Every biotech en­joys a good suc­cess sto­ry, and blue­bird bio $BLUE got their write­up in the New Eng­land Jour­nal of Med­i­cine. Pa­tient 1204 in blue­bird’s pro­gram for Lenti­Glo­bin gene ther­a­py pro­gram has had more than 15 months of fol­lowup, and his physi­cians say that the teenag­er has been free of the painful symp­toms of sick­le cell dis­ease, able to lead a nor­mal life and stop painful trans­fu­sions. That’s all a pos­i­tive, but blue­bird’s gene ther­a­py has al­so proven to be some­what vari­able among pa­tients. One suc­cess sto­ry does not make for a suc­cess­ful ther­a­py, but it’s still a plus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.